Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Joana M. Rodrigues"'
Autor:
Joana M. Rodrigues, Peter Hollander, Lina Schmidt, Eirinaios Gkika, Masoud Razmara, Darshan Kumar, Christian Geisler, Kirsten Grønbæk, Christian W. Eskelund, Riikka Räty, Arne Kolstad, Christer Sundström, Ingrid Glimelius, Anna Porwit, Mats Jerkeman, Sara Ek
Publikováno v:
Haematologica, Vol 109, Iss 4 (2023)
The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) remains to be determined. We performed an investigation of the expression of
Externí odkaz:
https://doaj.org/article/39c05dfdcc6f46b984fdbc58d95a8e72
Autor:
Agata M. Wasik, Nikolas Herold, Birger Christensson, Elin Ljung, Arne Kolstad, Georgios Z. Rassidakis, Björn E. Wahlin, Mats Jerkeman, Birgitta Sander, Mattias Carlsten, Mohammad H. A. Morsy, Joana M. Rodrigues, Magali Merrien, Sara Ek
Publikováno v:
Virchows Archiv
SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase (dNTPase) that restricts viral replication in infected cells and limits the sensitivity to cytarabine by hydrolysing its active metabolite, as recently shown in acute myeloid leukemia. Cyta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a08f94a2169d8142fc177a6ffa496d
https://doi.org/10.1007/s00428-021-03228-w
https://doi.org/10.1007/s00428-021-03228-w
Autor:
Arne Kolstad, Rose-Marie Amini, Caroline E. Weibull, Anna Nikkarinen, Peter Hollander, Joana M. Rodrigues, Riikka Räty, Mats Jerkeman, Anna Porwit, Sara Ek, Ingrid Glimelius
Publikováno v:
British Journal of Haematology
We characterised patients with mantle cell lymphoma (MCL) with poor prognosis based on differences in immune infiltration. Different expressions of the tumour cell markers Cyclin D1 and sex-determining region Y-box transcription factor 11 (SOX11), an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e75fb1f85d4dd4b851254d62e7ead279
https://pubmed.ncbi.nlm.nih.gov/33618428
https://pubmed.ncbi.nlm.nih.gov/33618428
Publikováno v:
Blood. 136:25-26
Introduction: Mantle Cell Lymphoma (MCL) is a B-cell neoplasm with poor prognosis and high relapse frequency. It follows an heterogenous clinical course and, despite clear improvements in survival among young and fit patients, most patients eventuall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e89f82df36d5fee265398ca3382fc67e
https://doi.org/10.1182/blood-2020-136944
https://doi.org/10.1182/blood-2020-136944
Autor:
Arne Kolstad, Sara Ek, A. Carlsson, Catja Freiburghaus, Kirsten Grønbæk, Simon Husby, Mats Jerkeman, Joana M. Rodrigues, Lavanya Lokhande, Christian Winther Eskelund
Publikováno v:
Hematological Oncology. 37:344-345
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c1e7cbf175444bfc7a3fc7b1ea3f1f1
https://doi.org/10.1002/hon.6_2631
https://doi.org/10.1002/hon.6_2631
Autor:
Mats Jerkeman, Magali Merrien, Agata M. Wasik, Elin Marin, Joana M. Rodrigues, Birger Christensson, Sara Ek, George Z. Rassidakis, Martin Lord, Birgitta Sander, Ioanna Xagoraris
Publikováno v:
Blood. 132:4136-4136
Introduction Mantle cell lymphoma (MCL) is an incurable disease with a median survival of 3-5 years. Most cases express SOX11, a transcription factor associated with MCL pathobiology, which serves as a diagnostic marker. Current standard first-line t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3600689b8e5d4f374c4f0954d238076a
https://doi.org/10.1182/blood-2018-99-118087
https://doi.org/10.1182/blood-2018-99-118087
Publikováno v:
Leukemia & Lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm that follows a heterogeneous clinical course. Recurrent mutations have been described, but their applicability in the clinical setting is currently limited. The main reasons are challenges i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d45fd540f7d2a2722fdc5268e6d1f0c